Nonglycemic effects of incretins in patients with long-term type 1 diabetes mellitus and chronic kidney disease
- Authors: Arutyunova MS1, Glazunova AM1, Mikhaleva OV2, Zuraeva ZT2, Martynov SA1, Klefortova II1, Manchenko OV1, Ulyanova IN1, Ilyin AV1, Shamkhalova MS.1, Shestakova MV3,4
-
Affiliations:
- «Эндокринологический научный центр» Минздрава России
- «Первый МГМУ им. И.М. Сеченова» Минздрава России
- «Эндокринологический научный центр» Минздрава России, Москва
- «Первый МГМУ им. И.М. Сеченова» Минздрава России, Москва
- Issue: Vol 87, No 10 (2015)
- Pages: 54-61
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31827
- ID: 31827
Cite item
Full Text
Abstract
About the authors
M S Arutyunova
«Эндокринологический научный центр» Минздрава РоссииМосква, Россия
A M Glazunova
«Эндокринологический научный центр» Минздрава РоссииМосква, Россия
O V Mikhaleva
«Первый МГМУ им. И.М. Сеченова» Минздрава РоссииМосква, Россия
Z T Zuraeva
«Первый МГМУ им. И.М. Сеченова» Минздрава РоссииМосква, Россия
S A Martynov
«Эндокринологический научный центр» Минздрава РоссииМосква, Россия
I I Klefortova
«Эндокринологический научный центр» Минздрава РоссииМосква, Россия
O V Manchenko
«Эндокринологический научный центр» Минздрава РоссииМосква, Россия
I N Ulyanova
«Эндокринологический научный центр» Минздрава РоссииМосква, Россия
A V Ilyin
«Эндокринологический научный центр» Минздрава РоссииМосква, Россия
M Sh Shamkhalova
«Эндокринологический научный центр» Минздрава РоссииМосква, Россия
M V Shestakova
«Эндокринологический научный центр» Минздрава России, Москва; «Первый МГМУ им. И.М. Сеченова» Минздрава России, Москва
References
- Jens J. Hoist The physiology and pharmacology of incretins in type 2 diabetes mellitus Journal Compilation 2008 Blackwell Publishing Ltd. Diabet, Obes Metabol. 2008;10(Suppl. 3):14-21.
- Дедов И.И., Шестакова М.В., Сухарева О.Ю. Инновации в лечении сахарного диабета 2 типа: применение инкретинов. Терапевтический архив. 2010;10:5-10.
- Бова Е.В., Пакус Е.Н. Использование инкретиномиметиков в лечении больных сахарным диабетом 2 типа. Фундаментальные исследования. 2009;10:6-9.
- Stonehouse AH, Darsow T, Maggs DG. Incretin-based therapies. J Diabetes. 2012;4(1):55-67.
- Сухарева О.Ю., Шмушкович И.А., Шестакова Е.А., Шестакова М.В. Система инкретинов при сахарном диабете 2-го типа: сердечно-сосудистые эффекты. Проблемы эндокринологии. 2012;6:33-42.
- Panchapakesan U, Mather A, Pollock C. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease. Clin Scie. 2013;124:17-26.
- Siemianowicz K, Francuz T, Garczorz W The influence of exendin and GLP-1 on VCAM-1 and ICAM-1 production in endothelium stimulated by TNF-α and glycated albumin. Health. 2012;4(12А):1570-1577.
- Skov J, Dejgaard A, Frokiaer J, Holst JJ, Jonassen T, Rittig S, Christiansen JS. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab. 2013;98(4):664-671. doi: 10.1210/jc.2012-3855.
- Gutzwiller JP, Hruz P, Huber AR, Hamel C, Zehnder C, Drewe J, Gutmann H, Stanga Z, Vogel D, Beglinger C Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion. 2006;73(2-3):142-150.
- Vallon V, Docherty NG. Intestinal regulation of urinary sodium excretion and the pathophysiology of diabetic kidney disease: a focus on glucagon-like peptide 1 and dipeptidyl peptidase 4. Exp Physiol. 2014;99(9):1140-1145. doi: 10.1113/expphysiol.2014.078766.
- Timper K, Grisouard J, Sauter NS, Herzog-Radimerski T, Dembinski K, Peterli R, M. Frey D, Keller U, Müller B, Christ-Crain M. Glucose-dependent insulinotropic polypeptide induces cytokine expression, lipolysis, and insulin resistance in human adipocytes. Am J Physiol Endocrinol Metab. 2013;304(1):1-13. doi: 10.1152/ajpendo.00100.2012.
- Harrison LB, Mora PF, Clark GO, Lingvay I. Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs. J Investig Med. 2013;61(1):40-44. doi:10.231/jim.0b013e318279b7d6.
- Dejgaard TF, Knop FK, Tarnow L, Frandsen CS, Hansen TS, Almdal T, Holst JJ, Madsbad S, Andersen HU. Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes — a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study. BMJ Open. 2015;5(4):e007791. doi: 10.1136/bmjopen-2015-007791.
- Шестакова Е.А., Ильин А.В., Шестакова М.В., Дедов И.И. Секреция гормонов инкретинового ряда у лиц с факторами риска развития сахарного диабета 2-го типа. Терапевтический архив. 2014(10):10-14.
- Plutzky J. The Incretin Axis in Cardiovascular Disease. Circulation. 2011;124:2285-2289. doi: 10.1161/circulationaha.111.06413.
- Ravassa S, Zudaire A, Diez J. GLP-1 and cardioprotection. From bench to bedside. Cardiovasc Res. 2012;94:316-332.
- Gomez N, Touihri K, Matheeussen V. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur JHeart Fail. 2012;14(1):14-22.
- Fields AV, Patterson B, Karnik AA, Shannon RP. Glucagon-like peptide-1 and myocardial protection: more than glycemic control. Clin Cardiol. 2009;32:236-243.
- Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962-965.
- Proudfoot D, Shanahan CM. Biology of calcification in vascular cells: intima versus media. Herz. 2001;26:245-251.
- London GM, Guerin AP, Marchais S. Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18:1731-1740.
- Budoff MJ, Hokanson JE, Nasir K, Shaw LJ, Kinney GL, Chow D, Demoss D, Nuguri V, Nabavi V, Ratakonda R, Berman DS, Raggi P. Progression of coronary artery calcium predicts all-cause mortality. JACC CardiovascImag. 2010;3(12):1229-1236.
- Jun-Kun Zhan, Pan Tan, Yan-Jiao Wang, Yi Wang, Jie-Yu He, Zhi-Yong Tang, Wu Huang, and You-Shuo Liu Exenatide can inhibit calcification of human VSMCs through the NF-kappa B/RANKL signaling pathway. CardiovascDiabetol. 2014;13:153-160. doi: 10.1186/s12933-014-0153-4.
- Changting Xiao, Satya Dash, Gary F. Lewis Mechanisms of Incretin Effects on Plasma Lipids and Implications for the Cardiovascular System. Cardiovasc Hematol Agents Med Chem. 2012;10:289-294.
- Ansar S, Koska J, Reaven PD. Postprandial hyperlipidemia, endothelial dysfun ction and cardiovascular risk: focus on incretins. Cardiovasc Diabetol. 2011;10:61-68.
- Шестакова М.В., Шамхалова М.Ш., Ярек-Мартынова И.Я., Клефортова И.И., Сухарева О.Ю., Викулова О.К., Зайцева Н.В., Мартынов С.А., Кварацхелия М.В., Тарасов Е.В., Трубицына Н.П. Сахарный диабет и хроническая болезнь почек: достижения, нерешенные проблемы и перспективы лечения. Сахарный диабет. 2011;1:81-88.
- Allen KV, Walker JD. Microalbuminuria and mortality in long-duration type 1 diabetes. Diabetes Care. 2003;26(8):2389-2391.
- Schlatter P, Beglinger C, Drewe J, Gutmann H. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept. 2007;141:120-128.
- Yamagishi S, Fukami K, Ueda S, Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets. 2007;8:952-959.
- Schlatter P, Beglinger C, Drewe J, Gutmann H. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept. 2007;141:120-128.
- Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem. 2002;277:20309-203015.
- Ishibashi Y, Nishino Y, Matsui T, Takeuchi M, Yamagishi SI. Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism. 2011;60:1271-1277.
- Tanaka T, HigashijimaY, Wada T, Nangaku M. The potential for renoprotection with incretin-based drugs. Kidney Intern. 2014;86:701-711.
- Kodera R, Shikata K, Kataoka HU. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia. 2011;54:965-978.
- Li W, Cui M, Wei Y. Inhibition of the expression of TGF-b1 and CTGF in human mesangial cells by exendin-4, a glucagon-like peptide-1 receptor agonist. CellPhysiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2012;30:749-757.
- Skov J. Effects of GLP-1 in the kidney. Rev Endocr Metab Disord. 2014;15(3):197-207. doi: 10.1007/s11154-014-9287-7.
- Jensen EP. Activation of renal GLP-1 receptors located in the afferent arteriole causes an increase in renal blood flow. Diabetologia. 2013;56:255-263.
- Nie Y, Ma RC, Chan JC, Xu H, Xu G. Glucose-dependent insulinotropic peptide impairs insulin signaling via inducing adipocyte inflammation in glucose-dependent insulinotropic peptide receptor-overexpressing adipocytes. FASEB J. 2012;26:2383-2393.
- Timper K, Grisouard J, Sauter NS, Herzog-Radimerski T, Dembinski K, Peterli R, Frey DM, Zulewski H, Keller U, Müller B, Christ-Crain M. Glucose-dependent insulinotropic polypeptide induces cytokine expression, lipolysis, and insulin resistance in human adipocytes. Am J Physiol — Endocrin Metabol. 2013;304(1):1-13. doi: 10.1152/ajpendo.00100.2012.
![](/img/style/loading.gif)